BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 49.4% in April

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 271,200 shares, a decrease of 49.4% from the March 31st total of 535,900 shares. Based on an average daily trading volume, of 345,100 shares, the days-to-cover ratio is currently 0.8 days.

BioCardia Price Performance

Shares of BCDA stock traded up $0.01 on Friday, hitting $0.38. 29,340 shares of the company’s stock were exchanged, compared to its average volume of 84,503. BioCardia has a 12 month low of $0.32 and a 12 month high of $2.92. The stock has a market cap of $10.12 million, a P/E ratio of -0.68 and a beta of 1.47. The company has a 50 day moving average of $0.41 and a 200 day moving average of $0.50.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 2,425.79%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.20 million. Sell-side analysts predict that BioCardia will post -0.42 EPS for the current fiscal year.

Insider Buying and Selling at BioCardia

In other news, CEO Peter Altman acquired 108,108 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were purchased at an average cost of $0.46 per share, with a total value of $49,729.68. Following the acquisition, the chief executive officer now directly owns 555,447 shares in the company, valued at approximately $255,505.62. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have bought a total of 111,358 shares of company stock valued at $50,942 in the last ninety days. 23.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BioCardia

A hedge fund recently raised its stake in BioCardia stock. CM Management LLC raised its position in BioCardia, Inc. (NASDAQ:BCDA) by 74.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 600,000 shares of the company’s stock after purchasing an additional 257,000 shares during the quarter. CM Management LLC owned 2.78% of BioCardia worth $258,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 20.57% of the company’s stock.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.